This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Total Brain Valuation

Is TTBL.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TTBL.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TTBL.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TTBL.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TTBL.F?

Key metric: As TTBL.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TTBL.F. This is calculated by dividing TTBL.F's market cap by their current revenue.
What is TTBL.F's PS Ratio?
PS Ratio	0.4x
Sales	AU$6.34m
Market Cap	AU$395.04k

TTBL.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TTBL.F's PS Ratio compare to its peers?

The above table shows the PS ratio for TTBL.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.2x
NVTA.Q Invitae	0.0002x	n/a	US$114.6k
ETAO.F ETAO International	0.00003x	n/a	US$1.5k
FCHS First Choice Healthcare Solutions	4.6x	n/a	US$108.8k
MEDV.F Medivolve	0.3x	n/a	US$198.6k
TTBL.F Total Brain	0.4x	n/a	US$267.4k

Price-To-Sales vs Peers: TTBL.F is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.3x).

Price to Sales Ratio vs Industry

How does TTBL.F's PS Ratio compare vs other companies in the US Healthcare Industry?

33 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$76.96b
CVS CVS Health	0.2x	4.6%	US$66.93b
COR Cencora	0.2x	6.4%	US$47.09b
CNC Centene	0.2x	5.7%	US$29.01b

33 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: TTBL.F is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is TTBL.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TTBL.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TTBL.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$5.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$76.83

-12.2%

12.7%

Patterson Companies

US$1.7b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$19.75

-5.0%

-38.3%

Enhabit

US$369.6m

Provides home health and hospice services in the United States.

EHAB

US$7.35

-6.8%

-25.2%